wide
array
model
avail
studi
respiratori
viral
infect
extrem
valuabl
develop
novel
therapeut
prophylact
option
highli
preval
diseas
addit
model
gather
consider
insight
cellular
molecular
mechan
involv
pathogenesi
infect
inflammatori
immun
respons
elicit
host
articl
review
new
promis
model
introduc
recent
field
section
editor
alastair
stewart
univers
melbourn
australia
long
interest
potenti
relationship
viral
respiratori
ill
chronic
respiratori
diseas
howev
rel
recent
attempt
develop
anim
model
address
chronic
influenc
acut
chronic
infect
professor
piedimont
colleagu
provid
commentari
impact
molecular
biolog
studi
viral
infect
address
import
issu
aris
select
appropri
strain
speci
model
cours
infect
inflamm
long
term
sequela
viral
respiratori
infect
remain
import
caus
morbid
mortal
worldwid
paramyxovirus
common
respiratori
pathogen
children
particular
respiratori
syncyti
viru
rsv
infect
nearli
children
within
first
two
year
life
result
hospit
annual
unit
state
immun
first
infect
complet
rsv
also
common
caus
respiratori
morbid
older
children
adult
mortal
elderli
addit
acut
care
cost
common
sequela
earlylif
rsv
infect
develop
recurr
wheez
asthma
new
paramyxoviru
genet
relat
rsv
human
metapneumoviru
hmpv
discov
recent
character
frequent
caus
lower
respiratori
tract
infect
common
viral
respiratori
pathogen
includ
influenza
virus
rhinovirus
adenovirus
given
consider
public
health
burden
import
develop
relev
diseas
model
use
vitro
vivo
silico
techniqu
better
understand
acut
chronic
effect
viral
infect
respiratori
tract
vitro
assay
use
mammalian
cell
long
use
model
diagnosi
prevent
therapi
respiratori
viral
infect
howev
actual
preval
respiratori
virus
probabl
underestim
use
diagnost
techniqu
lack
sensit
also
timeconsum
often
time
necessari
obtain
result
viral
cultur
exce
two
week
point
therapeut
option
respiratori
virus
virtual
useless
techniqu
improv
dramat
abil
diagnos
respiratori
viral
infect
real
time
pcr
analysi
use
detect
influenza
b
rsv
sever
acut
respiratori
syndromeassoci
coronavirus
sarscov
human
lung
transplant
recipi
pcr
use
rapidli
detect
respiratori
virus
sensit
significantli
better
avail
method
addit
studi
virus
acut
infect
pcr
also
use
ascertain
viral
persist
peripher
blood
mononuclear
cell
convalesc
phase
rapid
reversetranscript
pcr
introduc
recent
detect
rhinoviru
human
subject
excel
result
steining
colleagu
use
nest
rtpcr
abl
diagnos
rhinoviru
infect
within
h
versu
twoweek
delay
necessari
viral
cultur
similar
protocol
employ
research
studi
enterovirus
na
et
al
develop
multiplex
pcr
detect
type
serotyp
respiratori
adenoviru
similar
assay
develop
influenza
rsv
anoth
import
implic
pcr
sensit
enough
detect
respiratori
virus
store
biolog
materi
recent
multiplex
pcr
use
detect
respiratori
virus
archiv
nasal
swab
specimen
thu
allow
retrospect
diagnost
epidemiolog
work
pcr
techniqu
also
instrument
diagnosi
classif
new
pathogen
recent
addit
hmpv
paramyxovirida
famili
fig
one
recent
advanc
field
introduct
microarray
technolog
base
use
array
dna
probe
immobil
solid
support
simultan
identif
multipl
target
sequenc
microarray
use
diagnosi
viral
infect
also
molecular
type
investig
virushost
interact
gener
multiplex
random
pcr
amplif
viral
target
sequenc
clinic
specimen
increas
substanti
versatil
methodolog
earli
diagnosi
respiratori
viral
pathogen
particularli
crucial
import
clinic
practic
especi
alreadi
limit
therapeut
option
becom
even
less
effect
infect
progress
comprehens
unbias
analysi
viral
preval
given
biolog
set
facilit
mer
oligonucleotid
dna
microarray
capabl
detect
hundr
virus
simultan
viral
serotyp
distinguish
uniqu
hybrid
pattern
gener
viru
furthermor
combin
random
pcr
amplif
microarray
analysi
multipl
virus
detect
human
respiratori
specimen
without
use
sequencespecif
probe
expand
spectrum
detect
virus
singl
assay
wherea
simultan
provid
capabl
discrimin
among
viral
subtyp
recent
microarray
techniqu
use
diagnost
tool
track
evolut
sarscov
use
highthroughput
highdens
resequenc
array
wong
et
al
abl
defin
sarscov
mutat
associ
differ
clinic
pattern
studi
illustr
develop
valid
oligonucleotid
resequenc
array
entir
sarscov
genom
rapid
cost
effect
studi
sarscov
mutat
pattern
trace
index
case
contact
human
popul
made
much
easier
thu
dna
microarray
methodolog
ideal
global
epidemiolog
monitor
sarscov
smallgenom
pathogen
also
use
complementari
techniqu
type
subtyp
influenza
virus
could
lead
effect
track
flu
epidem
dna
microarray
also
use
recent
monitor
host
respons
induc
respiratori
virus
human
exampl
use
microarray
zhang
et
al
profil
kinet
pattern
chemokin
express
rsvinfect
lower
airway
epitheli
cell
particular
studi
explor
tempor
progress
epitheli
express
chemokin
factor
respons
recruit
activ
inflammatori
cell
rsvinfect
lower
airway
anim
model
provid
consider
insight
pathophysiolog
viral
respiratori
infect
mechan
virushost
interact
develop
candid
vaccin
vivo
model
also
use
simul
chronic
sequela
respiratori
viral
infect
human
commonli
use
anim
model
respiratori
viru
research
rodent
particularli
mice
mu
musculu
rat
rattu
norvegicu
guinea
pig
cavia
advantag
involv
use
rodent
includ
lower
purchas
cost
wide
avail
smallercheap
barrier
hous
facil
compar
larger
anim
use
nonhuman
primat
typic
reserv
respiratori
viru
vaccin
research
mous
model
develop
mani
virus
led
better
understand
immunopathogen
process
activ
infect
addit
mous
model
contribut
understand
viru
replic
airway
role
cytokin
chemokin
major
advantag
mous
model
wide
avail
reagent
specif
antibodi
studi
immunoinflammatori
signal
transduct
pathway
importantli
target
delet
overexpress
specif
gene
typic
conduct
mice
instrument
understand
molecular
basi
virushost
interact
contrast
small
size
litter
limit
use
model
studi
earlylif
infect
especi
physiolog
measur
involv
studi
usual
conduct
larger
rodent
like
rat
guinea
pig
caution
exercis
choos
rodent
model
experiment
respiratori
infect
signific
variat
differ
speci
strain
respond
pathogen
exampl
brown
norway
bn
rat
expos
respiratori
virus
mount
predomin
allerg
inflammatori
respons
follow
chronic
asthmalik
syndrom
stark
contrast
respons
fischer
rat
pathogen
develop
model
rsv
bronchiol
rat
uniqu
strain
mount
strong
immun
respons
clear
rsv
lung
much
like
selflimit
diseas
process
occur
normal
immunocompet
children
contrast
guinea
pig
mice
unabl
clear
viru
even
sever
month
develop
practic
lifelong
infect
highli
unusu
human
thu
model
particularli
use
studi
longterm
physiolog
abnorm
mild
transient
lower
respiratori
tract
infect
rsv
addit
inocul
weanl
rat
two
week
age
allow
evalu
longterm
effect
earli
rsv
infect
model
import
development
chang
distribut
neurogen
inflammatori
respons
across
respiratori
tract
observ
rat
age
stronger
inflammatori
respons
develop
lower
respiratori
tract
earli
life
might
explain
rsv
bronchiol
tend
occur
infant
wherea
infect
tend
restrict
upper
respiratori
tract
infect
older
children
adult
furthermor
remark
agerel
differ
found
mast
cell
distribut
leukotrienedepend
inflamm
express
neurotroph
factor
receptor
rsvinfect
lung
vivo
model
use
test
vaccin
antibodi
respiratori
virus
excel
exampl
palivizumab
fig
human
monoclon
antibodi
rsv
fusion
protein
prevent
spread
infect
lower
respiratori
tract
current
use
worldwid
passiv
prophylaxi
rsv
diseas
highrisk
infant
neutral
activ
antibodi
titrat
cotton
rat
protect
effect
rsvinduc
acut
airway
inflamm
chronic
hyperreact
apnea
shown
rat
fig
model
current
use
test
new
gener
potent
antirsv
antibodi
also
monoclon
antibodi
sarscov
nucleocapsid
protein
prepar
recent
immun
mice
anim
model
use
experi
new
strategi
gener
deliv
vaccin
human
recent
exampl
develop
recombin
multiepitop
peptid
compris
repeat
influenza
viru
hemagglutininneutr
epitop
express
escherichia
coli
administr
peptid
mice
rabbit
oryctolagu
cuniculu
induc
high
level
specif
antibodi
suggest
recombin
multiepitop
peptid
provid
new
way
develop
effect
vaccin
influenza
viru
new
techniqu
call
epiderm
powder
immun
epi
util
dermal
rout
deliveri
vaccin
recent
test
use
vivo
model
chen
et
al
inocul
mice
nonhuman
primat
influenza
vaccin
use
epi
demonstr
techniqu
evok
significantli
higher
serum
hemagglutin
inhibit
titer
tradit
intramuscular
rout
especi
combin
adjuv
epiderm
rout
vaccin
deliveri
also
evalu
rsv
vaccin
use
two
g
proteinderiv
molecul
attach
bacteri
enterotoxin
adjuv
demonstr
adequ
protect
rsv
mice
anoth
novel
prophylact
approach
rsv
util
chitosandna
nanospher
contain
cocktail
plasmid
dna
encod
rsv
antigen
suitabl
intranas
deliveri
mice
treat
nanospher
signific
reduct
viral
titer
viral
antigen
load
acut
rsv
infect
new
prophylact
strategi
increas
significantli
avail
vaccin
underdevelop
area
refriger
issu
avail
steril
syring
needl
furthermor
method
deriv
vivo
model
probabl
crucial
futur
rapid
mass
immun
known
newli
emerg
airborn
biolog
agent
past
two
decad
new
advanc
ad
layer
complex
research
biotechnolog
drug
discoveri
mani
newli
develop
techniqu
comput
natur
take
particular
disciplin
silico
collabor
mathemat
comput
biologist
scientist
particip
world
health
organ
global
influenza
surveil
network
result
number
mathemat
comput
advanc
increas
resolut
antigen
surveil
new
method
genet
analysi
viru
use
silico
techniqu
increas
abil
extract
inform
influenza
surveil
increas
quantit
data
avail
select
candid
vaccin
strain
silico
model
also
use
gener
rapid
diagnost
test
respiratori
virus
use
hexonbas
fluorogen
pcr
assay
rapid
typespecif
diagnost
system
adenoviru
type
develop
allow
earli
diagnosi
highrisk
patient
silico
model
also
gener
help
construct
vaccin
respiratori
virus
studi
sarscov
spike
glycoprotein
use
model
synthet
peptid
gener
six
peptid
sequenc
correspond
surfac
region
sarscov
subsequ
use
elicitspecif
antibodi
viru
synthet
peptidebas
approach
might
provid
insight
develop
sarscov
vaccin
silico
techniqu
also
use
molecular
epidemiolog
analysi
respiratori
virus
monitor
genet
divers
communitybas
studi
research
design
multiplex
nest
pcr
assay
analysi
clinic
specimen
subtyp
phylogenet
nucleotid
sequenc
rsv
surfac
g
glycoprotein
use
techniqu
research
abl
examin
retrospect
biolog
sampl
gather
fouryear
period
determin
emerg
two
new
subgroup
viru
anoth
studi
phylogenet
analysi
rhinoviru
isol
collect
success
epidem
season
show
strike
divers
viru
strain
circul
given
commun
viral
respiratori
infect
remain
import
caus
morbid
mortal
global
use
vitro
vivo
diseas
model
better
understand
gain
regard
pathophysiolog
acut
chronic
clinic
express
vitro
techniqu
pose
signific
advantag
vivo
model
particularli
wide
avail
rel
eas
setup
vitro
model
also
provid
rapid
detect
analysi
cytopath
effect
model
character
thoroughli
tend
reproduc
novel
vitro
techniqu
dna
microarray
allow
simultan
screen
multipl
viral
speci
strain
unfortun
mani
new
technolog
yet
wide
avail
clinician
also
requir
experienc
personnel
process
sampl
tabl
despit
broader
avail
lower
cost
vitro
analysi
vivo
model
remain
essenti
investig
mani
respiratori
viral
infect
chief
advantag
model
approxim
close
complex
inflammatori
pathway
cellcel
commun
pathogenhost
interact
work
human
often
produc
diseas
state
mimic
one
seen
clinic
practic
howev
discuss
care
consider
must
given
speci
also
strain
chosen
signific
variat
diseas
pattern
make
difficult
compar
vivo
model
given
respiratori
viru
nevertheless
vivo
model
still
remain
instrument
explor
acut
chronic
pathophysiolog
respiratori
viral
infect
well
develop
vaccin
antivir
antibodi
therapeut
advanc
biotechnolog
brought
forth
silico
techniqu
allow
rapid
accur
process
bioinformat
data
alreadi
use
success
monitor
respiratori
viru
outbreak
howev
model
underutil
present
requir
refin
increas
accept
use
scientif
commun
combin
diseas
model
present
articl
comprehens
investig
complex
aspect
known
emerg
respiratori
viral
infect
evolv
pathophysiolog
diagnosi
genom
epidemiolog
prevent
therapi
probabl
experi
rapid
dramat
progress
futur
